IP Library Granted Patent US 9,115,348
Granted Patent B2
US 9,115,348 · App. 13/671,120 · Granted Aug 25, 2015

Endoribonuclease compositions and methods of use thereof

Inventors: Rachel E. Haurwitz (Berkeley, CA); Jennifer A. Doudna (Berkeley, CA); Blake Wiedenheft (Oakland, CA); Martin Jinek (Berkeley, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12N9/22C07K1/22C07K14/8117C12P19/34C12Q1/6806C12Q1/6816C12Q1/6823
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,115,348
App. No.
13/671,120
Filed
Nov 7, 2012
Granted
Aug 25, 2015
Kind
B2
Art Unit
1652
USPC
435/194
Abstract

The present disclosure provides variant Csy4 endoribonucleases, nucleic acids encoding the variant Csy4 endoribonucleases, and host cells genetically modified with the nucleic acids. The variant Csy4 endoribonucleases find use in a variety of applications, which are also provided. The present disclosure also provides methods of detecting a specific sequence in a target polyribonucleotide; and methods of regulating production of a target RNA in a eukaryotic cell.

Claims (25)

1. A variant Csy4 endoribonuclease comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:8, wherein the variant Csy4 endoribonuclease comprises an amino acid substitution at His-29, wherein the variant Csy4 endoribonuclease is enzymatically inactive in the absence of imidazole, and wherein the variant Csy4 endoribonuclease is activatable in the presence of imidazole.

2. The variant Csy4 endoribonuclease of claim 1 , wherein the amino acid substitution is a His29 to Ala29 substitution.

3. The variant Csy4 endoribonuclease of claim 1 , wherein the variant Csy4 endoribonuclease comprises a moiety that provides a detectable signal.

4. The variant Csy4 endoribonuclease of claim 3 , wherein the moiety that provides a detectable signal is a fluorophore, a quantum dot, an enzyme other than the endoribonuclease, or a nanoparticle.

5. The variant Csy4 endoribonuclease of claim 1 , wherein the endoribonuclease is immobilized on an insoluble support.

6. The variant Csy4 endoribonuclease of claim 5 , wherein the insoluble support is a bead.

7. The variant Csy4 endoribonuclease of claim 1 , wherein, in the variant Csy4 endoribonuclease binds an RNA substrate comprising the nucleotide sequence 5′-GUUCACUGCCGUAUAGGCAGCUAAGAAA-3′ (SEQ ID NO:1).

8. A kit for purifying a target RNA present in a mixed population of nucleic acids, the kit comprising:

the variant Csy4 endoribonuclease of claim 1 .

9. The kit of claim 8 , further comprising a recombinant expression vector comprising, in order from 5′ to 3′ and in operable linkage:

a) a nucleotide sequence encoding an RNA substrate that is specifically bound by the variant Csy4 endoribonuclease of claim 1 ;

b) a multiple cloning site suitable for insertion of a nucleic acid encoding the target RNA.

10. The kit of claim 9 , wherein the nucleotide sequence encoding the RNA substrate is operably linked to a promoter.

11. The kit of claim 10 , wherein the promoter is an inducible promoter.

12. The kit of claim 9 , wherein the RNA substrate comprises the nucleotide sequence 5′-GUUCACUGCCGUAUAGGCAGCUAAGAAA-3′ (SEQ ID NO:1).

13. The kit of claim 9 , wherein the recombinant expression vector comprises, inserted into the multiple cloning site, a nucleotide sequence encoding the target RNA.

14. The kit of claim 8 , further comprising imidazole.

15. The kit of claim 8 , further comprising one or more wash buffers.

16. The kit of claim 8 , further comprising a positive control expression vector.

17. The kit of claim 8 , wherein the variant Csy4 endoribonuclease is immobilized on an insoluble support.

18. A method of isolating a target RNA present in a mixed population of nucleic acids, the method comprising:

a) contacting a mixed population of nucleic acids with the variant Csy4 endoribonuclease of claim 1 , where the variant Csy4 endoribonuclease is immobilized on an insoluble support, wherein the mixed population of nucleic acids comprises a tagged target RNA comprising a recognition nucleotide sequence that is specifically bound by the immobilized variant Csy4 endoribonuclease, forming a tagged target RNA-immobilized variant Csy4 endoribonuclease complex, wherein said contacting is carried out in a binding solution lacking imidazole;

b) adding imidazole to the binding solution to a final concentration of from about 100 mM to about 500 mM, thereby forming a reactivation solution that enzymatically reactivates the immobilized variant Csy4 endoribonuclease, wherein the reactivated immobilized variant Csy4 endoribonuclease cleaves the target RNA from the tag; and

c) collecting the released target RNA.

19. The method of claim 18 , further comprising a wash step carried out after step (a) and before step (b).

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 4, 2013
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029748/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2013
From: HAURWITZ, RACHEL E.; DOUDNA, JENNIFER A.; WIEDENHEFT, BLAKE; JINEK, MARTIN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 029577/0834 →
Continuity (5)
Continuation In Part PCTUS2011035775 · May 9, 2011
Provisional Application 61333163 · May 10, 2010
Provisional Application 61365627 · Jul 19, 2010
Provisional Application 61413287 · Nov 12, 2010
Related Publication 20130130248A1 · May 23, 2013